Early clinical effects of accelerated UVA/riboflavin corneal collagen cross-linking combined with LASIK for myopia
WU Ying,TIAN Lei,ANG Liqiang,E Mei,UANG Yifei
Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China; Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Lab, Beijing 100730, China
Objective To evaluate at six months after myopia surgery the clinical effects of laser in situ keratomileusis (LASIK) combined with accelerated UVA/riboflavin corneal collagen cross-linking (ACXL). Methods This was a prospective and self-controlled study that included 18 myopia patients (36 eyes). LASIK was performed using femtosecond and excimer lasers. Before the flap was reset, single-use Vibe Xtra riboflavin drops were instilled in the corneal stromal bed for 90 seconds. A KXL system (Avedro Inc.) was used to irradiate the cornea with UVA light, delivering 30 mW/cm2 of irradiance for 90 seconds. The total exposure dose was 2.7 J/cm2. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), spherical equivalent (SE), corneal topography, thinnest corneal thickness (TCT), and endothelial cell density (ECD) were evaluated preoperatively and six months postoperatively. Paired t-test were used for statistical analysis. Results Mean UCVA changed from 0.93±0.34 (logMAR) to -0.05±0.08, SE from -8.03±1.86 diopter (D) to -0.29±0.39 D, keratometry from 44.79±2.10 D to 37.96±2.32 D, TCT from 524.6±25.2 µm to 437.7±27.0 µm, corneal peak distance from 5.48±0.31 mm to 4.99±0.44 mm, and corneal deformation amplitude from 1.09±0.12 mm to 1.18±0.18 mm. Aside from the ECD and highest corneal concavity radius, changes in the remaining parameters between preoperative and six-month postoperative values were significant (t=-63.02～26.87, P＜0.05). None of the patients developed signs of significant regression, ectasia, or keratitis during the follow-up period. Conclusion LASIK combined with ACXL can effectively correct refractive error in patients with myopia. There were no significant complications during the six-month follow-up. But the long-term effects and indications of LASIK combined with ACXL need to be further observed and studied.
Lawless M, Hodge C. LASIK[J]. Int Ophthalmol Clin,2013, 53(1):111-128. DOI:10.1097/IIO.0b013e318271346e.
[2]
Randleman JB, Russell B, Ward MA, et al. Risk factors and prognosis for corneal ectasia after LASIK[J]. Ophthalmology, 2003,110(2):267-275. DOI:10.1016/S0161-6420(02)01727-X.
[3]
Wollensak G. Crosslinking treatment of progressive keratoconus: new hope[J]. Curr Opin Ophthalmol,2006,17(4):356-360. DOI: 10.1097/01.icu.0000233954.86723.25.
[4]
Brittingham S, Tappeiner C, Frueh BE. Corneal cross-linking in keratoconus using the standard and rapid treatment protocol: differences in demarcation line and 12-month outcomes[J]. Invest Ophthalmol Vis Sci,2014,55(12):8371-8376. DOI:10.1167/iovs.14- 15444.
Kanellopoulos AJ. Long-term safety and efficacy follow-up of prophylactic higher fluence collagen cross-linking in high myopic laser-assisted in situ keratomileusis[J]. Clin Ophthalmol,2012, 6:1125-1130. DOI:10.2147/OPTH.S31256.
[8]
Dupps WJ. Biomechanical modeling of corneal ectasia[J]. J Refract Surg,2005,21(2):186-190.
[9]
Rad AS, Jabbarvand M, Saifi N. Progressive keratectasia after laser in situ keratomileusis[J]. J Refract Surg,2004,20(5 Suppl):S718-722.
[10]
Binder PS. Analysis of ectasia after laser in situ keratomileusis: risk factors[J]. J Cataract Refract Surg,2007,33(9):1530-1538. DOI:10.1016/j.jcrs.2007.04.043.
[11]
Chayet AS, Assil KK, Montes M, et al. Regression and its mechanisms after laser in situ keratomileusis in moderate and high myopia[J]. Ophthalmology,1998,105(7):1194-1199. DOI: 10.1016/S0161-6420(98)97020-8.
[12]
Raiskup F, Theuring A, Pillunat LE, et al. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results[J]. J Cataract Refract Surg,2015, 41(1):41-46. DOI:10.1016/j.jcrs.2014.09.033.
[13]
Richoz O, Mavrakanas N, Pajic B, et al. Corneal collagen cross-linking for ectasia after LASIK and photorefractive keratectomy: long-term results[J]. Ophthalmology,2013,120(7):1354-1359. DOI:10.1016/j.ophtha.2012.12.027.
[14]
Rocha KM, Ramos-Esteban JC, Qian Y, et al. Comparative study of riboflavin-UVA cross-linking and "flash-linking" using surface wave elastometry[J]. J Refract Surg,2008,24(7):S748-751.
[15]
Kanellopoulos AJ. Comparison of sequential vs same-day simultaneous collagen cross-linking and topography-guided PRK for treatment of keratoconus[J]. J Refract Surg,2009,25(9):S812-818. DOI:10.3928/1081597X-20090813-10.
[16]
Tomita M, Mita M, Huseynova T. Accelerated versus conventional corneal collagen crosslinking[J]. J Cataract Refract Surg,2014, 40(6):1013-1020. DOI:10.1016/j.jcrs.2013.12.012.
[17]
Patel NP, Clinch TE, Weis JR, et al. Comparison of visual results in initial and re-treatment laser in situ keratomileusis procedures for myopia and astigmatism[J]. Am J Ophthalmol, 2000,130(1):1-11.
[18]
Hersh PS, Fry KL, Bishop DS. Incidence and associations of retreatment after LASIK[J]. Ophthalmology,2003,110(4):748-754. DOI:10.1016/S0161-6420(02)01981-4.
[19]
Randleman JB, White AJ, Lynn MJ, et al. Incidence, outcomes, and risk factors for retreatment after wavefront-optimized ablations with PRK and LASIK[J]. J Refract Surg,2009,25(3):273-276.
[20]
Mimouni M, Vainer I, Shapira Y, et al. Factors Predicting the Need for Retreatment After Laser Refractive Surgery[J]. Cornea,2016,35(5):607-612. DOI:10.1097/ICO.0000000000000795.
[21]
Roberts CJ. Concepts and misconceptions in corneal biomechanics[J]. J Cataract Refract Surg,2014,40(6):862-869. DOI:10.1016/ j.jcrs.2014.04.019.
[22]
Chen MC, Lee N, Bourla N, et al. Corneal biomechanical measurements before and after laser in situ keratomileusis[J]. J Cataract Refract Surg,2008,34(11):1886-1891. DOI:10.1016/ j.jcrs.2008.06.035.
[23]
Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin cross-linking of the cornea[J]. Cornea,2007,26(4):385-389. DOI:10.1097/ICO.0b013e3180334f78.
浙公网安备 33030202001892号